Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
Anhui Anke Biotechnology Group Co Ltd
Net Income (Common)
Anhui Anke Biotechnology Group Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Anhui Anke Biotechnology Group Co Ltd
SZSE:300009
|
Net Income (Common)
¥782.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
22%
|
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-¥94.6m
|
CAGR 3-Years
67%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Net Income (Common)
-¥514.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Net Income (Common)
-¥266.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Anhui Anke Biotechnology Group Co Ltd
Glance View
Anhui Anke Biotechnology Group Co., Ltd., nestled in the heart of China's Anhui Province, weaves a story that blends innovation with a commitment to health. Founded in 1986, Anke Biotechnology made its mark early by focusing on the development and manufacturing of biopharmaceutical products. The company's narrative is rooted in its pursuit of cutting-edge technology, specifically in the fields of genetic engineering, fermentation technology, and vaccine production. As China looks to bolster its biopharmaceutical sector, Anke stands out with its robust pipeline of recombinant protein drugs and vaccines that cater to widespread public health needs. By leveraging advanced bioengineering processes, the company aims to encapsulate scientific complexity into tangible, life-saving treatments. At the core of its operations is a diverse business model that spans research, development, production, and commercialization of healthcare products. Through strategic alliances and continuous investment in R&D, Anke Biotechnology sustains a competitive edge by bringing innovative therapies to market. Revenue flows from its flagship products like recombinant human growth hormones and interferons, which address critical healthcare demands not just within China, but internationally as well. Furthermore, the company astutely capitalizes on the rising healthcare needs of an aging population, along with the increasing importance of preventive medicine, reflected in its vaccine offerings. It’s this strategic acumen, blended with scientific prowess, that allows Anhui Anke Biotechnology to thrive in an industry characterized by rapid innovation and evolving challenges.
See Also
What is Anhui Anke Biotechnology Group Co Ltd's Net Income (Common)?
Net Income (Common)
782.5m
CNY
Based on the financial report for Sep 30, 2024, Anhui Anke Biotechnology Group Co Ltd's Net Income (Common) amounts to 782.5m CNY.
What is Anhui Anke Biotechnology Group Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
22%
Over the last year, the Net Income (Common) growth was 3%. The average annual Net Income (Common) growth rates for Anhui Anke Biotechnology Group Co Ltd have been 17% over the past three years , 22% over the past five years , and 22% over the past ten years .
You don't have any saved screeners yet